Cassava Sciences with ticker code (SAVA) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 24 and 14 with a mean TP of 19.33. Now with the previous closing price of 7.83 this indicates there is a potential upside of 146.9%. The day 50 moving average is 8.38 and the 200 day MA is 6.22. The company has a market cap of $265m. Visit the company website at: http://www.cassavasciences.com
Cassava Sciences, a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer’s disease. The company was formerly known as Pain Therapeutics and changed its name to Cassava Sciences in March 2019. Cassava Sciences was founded in 1998 and is based in Austin, Texas.